Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Dasom Lee, Brian J. Sworder, Lara Stepan, Abood Okal, Chang-Pin Huang, Xiaoman Kang, James Hamilton, Charles Macaulay, Mari Olsen, Chih Long Liu, Maximilian Diehn, Leanne Peiser, David Kurtz, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2024-200924

Published: 2024

Journal Articles

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mark Roschewski, David M. Kurtz, Jason Westin, Ryan C. Lynch, Charles Macaulay, Christian Kuffer, Gregory J. Hogan, Sandra Close, Jacob J. Chabon, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh, Andre Schultz

Blood (2022) 140 (Supplement 1): 785–786.

https://doi.org/10.1182/blood-2022-167936

Published: 2022

Journal Articles

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1301–1303.

https://doi.org/10.1182/blood-2022-165545

Published: 2022

Journal Articles

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 8609–8610.

https://doi.org/10.1182/blood-2022-170087

Published: 2022

Journal Articles

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Blood (2021) 138 (Supplement 1): 6.

https://doi.org/10.1182/blood-2021-149644

Published: 2021

Journal Articles

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Mohammad Shahrokh Esfahani, Stefan Alig, Mahya Mehrmohamadi, Emily G. Hamilton, Daniel A King, Andre Schultz, Chloe B. Steen, Charles Macaulay, Brian Sworder, David M. Kurtz, Maximilian Diehn, Ash A. Alizadeh

Blood (2021) 138 (Supplement 1): 37.

https://doi.org/10.1182/blood-2021-150964

Published: 2021

Journal Articles

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Navika D Shukla, Alexander F. M. Craig, MPhil, Brian Sworder, MD PhD, David M. Kurtz, MDPhD, Charles Macaulay, MSc, BA, Andrea Garofalo, BS, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, George Duran, BA, Youn H. Kim, MD, James Zehnder, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD, Maximilian Diehn, MD PhD, Michael S. Khodadoust, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-141655

Published: 2020

Journal Articles

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Blood (2020) 136 (Supplement 1): 53–54.

https://doi.org/10.1182/blood-2020-139605

Published: 2020

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Mohammad Shahrokh Esfahani, Stefan Alig, MD, David M. Kurtz, MD PhD, Joanne Soo, MD, Michael C. Jin, BS, Charles Macaulay, MSc, BA, Alexander F. M. Craig, MPhil, Andrea Garofalo, BS, BA, Chloe B. Steen, MSc, Florian Scherer, MD, Brian Sworder, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 551.

https://doi.org/10.1182/blood-2019-132069

Published: 2019

Journal Articles

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

David M. Kurtz, MD PhD, Joanne Soo, MD, Stefan Alig, MD, Lyron Co Ting Keh, Charles Macaulay, Michael C. Jin, BS, Florian Scherer, MD, Emily G. Hamilton, BS, Chih Long Liu, PhD, Binbin Chen, PhD, Alexander F. M. Craig, MPhil, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 552.

https://doi.org/10.1182/blood-2019-131267

Published: 2019

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2018-99-119140

Published: 2018

NARROW

Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only